血漿中カルバマゼピン波度測定におけるSLFIA法の評価 : EMIT法およびHPLC法との比較

概要

論文の詳細を見る
Concentrations of carbamazepine (CBZ) in plasma were measured by AMES TDA^<TM> carbamazepine kit, a newly developed substrate-labeled fluorescent immunoassay (SLFIA). The study produced results which showed good correlation with those of homogeneous enzyme immunoassay (EMIT) and high-performance liquid chromatography (HPLC). There was a significant correlation in the plasma concentrations between SLFIA and EMIT methods (n=92, r=0.994, p<0.01), where as a high correlation between SLFIA and HPLC was also found (n=92, r=0.990, p<0.01). For the determination of plasma concentrations of antiepileptics in the clinical field, SLFIA procedure seems to have considerable advantages over hitherto available method: This method requires only 50 μl of plasma for a single determination and is quite a simple method for monitoring plasma concentrations of antiepileptics. Concentrations of CBZ in plasma after administration of CBZ alone were compared with those after concurrent administration of antiepileptics, including CBZ, Phenobarbital (PB) and phenytoin (PHT). From these results, it was found that plasma concentrations of CBZ administered concurrently with PB and PHT were significantly lower than those after administration of CBZ alone.
日本医療薬学会の論文
1985-10-20